Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 94,144 Shares

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 94,144 shares of the stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $4.39, for a total transaction of $413,292.16. Following the sale, the chief executive officer now directly owns 15,204,752 shares in the company, valued at $66,748,861.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

David Zaccardelli also recently made the following trade(s):

• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Trading Down 2.1 %

NASDAQ VRNA opened at $37.59 on Thursday. The firm’s fifty day moving average price is $31.28 and its 200 day moving average price is $22.59. Verona Pharma plc has a 12 month low of $11.39 and a 12 month high of $39.40. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. The company has a market capitalization of $3.05 billion, a price-to-earnings ratio of -19.58 and a beta of 0.42.

Verona Pharma (NASDAQ:VRNA) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The business had revenue of $5.62 million during the quarter, compared to the consensus estimate of $2.31 million. During the same quarter last year, the firm posted ($0.18) earnings per share. On average, sell-side analysts expect that Verona Pharma plc will post -2.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VRNA. CWM LLC purchased a new stake in Verona Pharma in the second quarter valued at approximately $29,000. EMC Capital Management acquired a new position in shares of Verona Pharma in the 2nd quarter valued at $38,000. GAMMA Investing LLC raised its position in Verona Pharma by 70.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock valued at $38,000 after purchasing an additional 553 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after purchasing an additional 529 shares during the period. Finally, Legato Capital Management LLC purchased a new position in Verona Pharma during the 2nd quarter worth $154,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on VRNA shares. Wells Fargo & Company lifted their price target on shares of Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a research note on Tuesday. Truist Financial lifted their price objective on shares of Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Canaccord Genuity Group increased their target price on Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a report on Tuesday. Finally, HC Wainwright raised their price target on Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $43.83.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.